Meeting
2019 Gastrointestinal Cancers Symposium
Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma.
Authors
Angel Alsina
Tampa General Hospital, Tampa, FL
Angel Alsina , Masatoshi Kudo , Arndt Vogel , Ann-Lii Cheng , Won Young Tak , Baek-Yeol Ryoo , T.R. Jeffry Evans , Carlos López-López , Bruno Daniele , Soamnauth Misir , Min Ren , Namiki Izumi , Shukui Qin , Richard S. Finn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01761266
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 371)
DOI
10.1200/JCO.2019.37.4_suppl.371
Abstract #
371
Poster Bd #
K11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of lenvatinib (LEN) vs sorafenib (SOR) in the first-line (1L) treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC): A post hoc analysis of patients with nonviral etiology from REFLECT.
First Author: Ari David Baron
Poster
2021 ASCO Annual Meeting
The cost effectiveness of lenvatinib versus atezolizumab and bevacizumab or sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in Canada.
First Author: David Trueman
Poster
2020 Gastrointestinal Cancers Symposium
Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC).
First Author: Angel Alsina
Poster
2021 Gastrointestinal Cancers Symposium
Post hoc analysis in patients (pts) with unresectable hepatocellular carcinoma (uHCC) who progressed to Child-Pugh B (CPB) liver function in the phase III REFLECT study of lenvatinib (LEN).
First Author: Jasmine Huynh